These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7553650)

  • 21. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
    Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
    Bechtel MJ; Reinartz J; Rox JM; Inndorf S; Schaefer BM; Kramer MD
    Exp Cell Res; 1996 Mar; 223(2):395-404. PubMed ID: 8601416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
    Durko M; Brodt P
    Biochem Biophys Res Commun; 1998 Jun; 247(2):342-8. PubMed ID: 9642128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
    Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
    J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
    Liu JW; Wei DZ; Du CB; Zhong JJ
    Acta Pharmacol Sin; 2003 Feb; 24(2):102-8. PubMed ID: 12546716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of the plasmin system in human mammary pathology using immunofluorescence.
    Clavel C; Chavanel G; Birembaut P
    Cancer Res; 1986 Nov; 46(11):5743-7. PubMed ID: 2428483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
    Grøndahl-Hansen J; Ralfkiaer E; Kirkeby LT; Kristensen P; Lund LR; Danø K
    Am J Pathol; 1991 Jan; 138(1):111-7. PubMed ID: 1702928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
    Protiva P; Sordat I; Chaubert P; Saraga E; Trân-Thang C; Sordat B; Blum AL; Dorta G
    Br J Cancer; 1998; 77(2):297-304. PubMed ID: 9461001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
    Meissauer A; Kramer MD; Schirrmacher V; Brunner G
    Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator system: implications for mammary cell growth and involution.
    Politis I
    J Dairy Sci; 1996 Jun; 79(6):1097-107. PubMed ID: 8827475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
    Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
    J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
    Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
    J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GB (guanidinobenzoatase) cell surface protease and serum inhibitors in colorectal neoplasia.
    Steven FS; Griffin MM; Talbot IC
    J Pathol; 1992 May; 167(1):19-24. PubMed ID: 1625054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.